RxDoctor Payments Data

Ashlyn Brewster

Acute Care · Naples, FLNPI 1144094566

Payments from drug & device makers

$965in general payments, 2019–2025

Across 27 payments — averaging $35.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$375
  • Edwards Lifesciences$188
  • Alnylam Pharmaceuticals Inc.$111
  • Johnson & Johnson$61
  • Amgen$59
  • Novartis$45
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$965100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$965 in reported general payments places this provider in the 70th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Medicare billing

Part B allowed, 2024
$126,205
Medicare patients
725
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$119,303
JardianceEmpagliflozin43$52,815
EntrestoSacubitril/Valsartan27$48,972
XareltoRivaroxaban34$44,765
Repatha SureclickEvolocumab50$41,072
FarxigaDapagliflozin Propanediol16$19,616
VascepaIcosapent Ethyl14$7,498
Atorvastatin Calcium190$2,713
Ranolazine ErRanolazine18$2,243
Prasugrel Hcl37$1,967
ClopidogrelClopidogrel Bisulfate162$1,742
Metoprolol Succinate148$1,704
Losartan Potassium106$1,558
Spironolactone35$642
Rosuvastatin Calcium57$575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$45$48,97227 claims
Johnson & JohnsonXarelto$61$44,76534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,150 acute care providers in Florida.

Other acute care in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →